Brekiya Injection
Product Images NDC 64896-509

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Brekiya (NDC 64896-509). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Brekiya Dihydroergotamine Mesylate Injection 1)

Chemical structure of dihydroergotamine mesylate, showing its molecular arrangement with labeled atoms and bonds, accompanied by the molecular formula CH3SO3H.*

FDA Label Image

1 (Brekiya Dihydroergotamine Mesylate Injection 10)

An illustration showing the front view of a person's thighs and lower torso, highlighting two areas on the upper front thighs shaded in blue, likely indicating recommended injection sites for a subcutaneous injection.*

FDA Label Image

1 (Brekiya Dihydroergotamine Mesylate Injection 11)

An instructional illustration showing a person applying a patch or a similar adhesive bandage to their upper thigh area. The person is seated, wearing shorts, and using one hand to press the adhesive onto the skin.*

FDA Label Image

1 (Brekiya Dihydroergotamine Mesylate Injection 12)

Illustration showing the preparation steps for BREKIYA (Dihydroergotamine Mesylate) 1 mg/mL subcutaneous injection. The image depicts hands removing the red needle cap and the outer pull-off cap from the pen injector device, highlighting the white safety guard.*

FDA Label Image

1 (Brekiya Dihydroergotamine Mesylate Injection 13)

Illustration showing how to hold and position a subcutaneous injection device at a 90-degree angle to the skin on the thigh, demonstrating proper injection technique for a product like BREKIYA (dihydroergotamine mesylate) injection.*

FDA Label Image

1 (Brekiya Dihydroergotamine Mesylate Injection 14)

An instructional illustration showing a person administering a subcutaneous injection with an autoinjector device into the thigh. The image includes a hand pressing the device down against the skin with a downward green arrow and the text "Push Down" to indicate the injection action.*

FDA Label Image

1 (Brekiya Dihydroergotamine Mesylate Injection 15)

An instructional illustration showing the subcutaneous injection technique for BREKIYA (Dihydroergotamine Mesylate) injection. It demonstrates holding the injection device vertically over the thigh, pressing and releasing the button to deliver the dose, with an arrow indicating the press and release action and a label for the first click.*

FDA Label Image

1 (Brekiya Dihydroergotamine Mesylate Injection 16)

An instructional illustration showing a person administering a subcutaneous injection using a pen device. The hand holds the pen vertically to the thigh, with an arrow and text indicating to keep holding down after the second click for 10 seconds. The person is wearing shorts exposing the thigh injection site.*

FDA Label Image

1 (Brekiya Dihydroergotamine Mesylate Injection 17)

An instructional illustration showing the proper use of the BREKIYA injection pen containing Dihydroergotamine Mesylate. The image depicts a person holding the pen perpendicular to their thigh for subcutaneous injection, with a close-up inset highlighting the correct position of the window indicator on the pen.*

FDA Label Image

1 (Brekiya Dihydroergotamine Mesylate Injection 18)

Illustration showing a hand holding a pink injection device positioned near the thigh. An upward-pointing green arrow labeled 'Lift Up' indicates the motion to lift the device. The illustration appears to demonstrate the usage technique for a subcutaneous injection device.*

FDA Label Image

1 (Brekiya Dihydroergotamine Mesylate Injection 19)

Illustration showing a hand holding a BREKIYA injection pen with 1 mg/mL dihydroergotamine mesylate, disposing of the pen needle into a sharps disposal container. The image demonstrates safe disposal of the subcutaneous injection device.*

FDA Label Image

1 (Brekiya Dihydroergotamine Mesylate Injection 2)

BREKIYA 1 mg/mL (dihydroergotamine mesylate) injection autoinjector. The label shows the product name, generic name, concentration, and dosage form as a subcutaneous injection autoinjector. Labeled by Amneal Pharmaceuticals LLC.*

FDA Label Image

1 (Brekiya Dihydroergotamine Mesylate Injection 20)

An instructional illustration showing a person applying a small adhesive patch to the skin on their thigh. The individual is seated and wearing shorts. The image suggests a step in the preparation or administration process related to the drug.*

FDA Label Image

1 (Brekiya Dihydroergotamine Mesylate Injection 21)

BREKIYA 1 mg/mL (dihydroergotamine mesylate) injection in a prefilled single-dose subcutaneous autoinjector. The label states it is for subcutaneous injection only and lists active and inactive ingredients. Distributed by Amneal Specialty, a division of Amneal Pharmaceuticals LLC, Bridgewater, NJ. The label includes NDC 64896-509 and manufacturing details.*

FDA Label Image

1 (Brekiya Dihydroergotamine Mesylate Injection 22)

Label for BREKIYA 1 mg/mL injection, a dihydroergotamine mesylate subcutaneous autoinjector. The label indicates it is a 1 mL prefilled single-dose autoinjector, manufactured by Amneal Pharmaceuticals Pvt. Ltd. and distributed by Amneal Pharmaceuticals LLC. Storage guidelines, caution regarding latex allergy, and barcode are visible. The label includes a blank overcoding area for batch and expiration date printing.*

FDA Label Image

1 (Brekiya Dihydroergotamine Mesylate Injection 23)

Packaging label for BREKIYA (dihydroergotamine mesylate) injection 1 mg/mL subcutaneous autoinjector. The label shows the brand name, generic name, strength, dosage form, and route. Manufactured by Amneal Pharmaceuticals Pvt. Ltd., India, and distributed by Amneal Specialty, a division of Amneal Pharmaceuticals LLC, Bridgewater, NJ. The label includes a barcode and prescribing information references.*

FDA Label Image

1 (Brekiya Dihydroergotamine Mesylate Injection 3)

BREKIYA 1 mg/mL dihydroergotamine mesylate injection for subcutaneous use. The label shows the product name with pronunciation, the generic name, and indicates it is an injection intended for subcutaneous administration. Manufactured by Amneal Pharmaceuticals LLC.*

FDA Label Image

1 (Brekiya Dihydroergotamine Mesylate Injection 4)

BREKIYA 1 mg/mL injection autoinjector for subcutaneous use contains dihydroergotamine mesylate. The autoinjector features a red needle cap, viewing window, and gray activation button. The product is labeled by Amneal Pharmaceuticals LLC and includes the NDC 64896-509-01.*

FDA Label Image

1 (Brekiya Dihydroergotamine Mesylate Injection 5)

An instructional illustration showing a used BREKIYA (dihydroergotamine mesylate) 1 mg/mL subcutaneous auto-injector. The image highlights the removal of the red needle cap, the presence of the white safety guard covering the needle, and the viewing window displaying a blue plunger rod filled inside the injector.*

FDA Label Image

1 (Brekiya Dihydroergotamine Mesylate Injection 6)

Illustration showing hands being washed under running water from a faucet in a sink, with a soap dispenser visible in the background. The image emphasizes hand hygiene.*

FDA Label Image

1 (Brekiya Dihydroergotamine Mesylate Injection 7)

Illustration showing the contents of the BREKIYA (Dihydroergotamine Mesylate) subcutaneous injection kit. It includes a foil pouch containing the BREKIYA autoinjector, alcohol swabs, cotton balls or gauze, and a red sharps container for safe disposal of the injection materials.*

FDA Label Image

1 (Brekiya Dihydroergotamine Mesylate Injection 8)

Illustration showing BREKIYA 1 mg/mL subcutaneous injection packaging and usage. The image depicts a sealed, silver foil pouch with a label containing product information, including the brand name BREKIYA and active ingredient dihydroergotamine mesylate. The lower part shows hands opening the pouch by a tear notch and removing the prefilled injection device.*

FDA Label Image

1 (Brekiya Dihydroergotamine Mesylate Injection 9)

An instructional illustration showing a hand holding a BREKIYA injection pen for subcutaneous use. The image highlights a viewing window and points to the expiration date on the label of the pen. The product is identified as BREKIYA, dihydroergotamine mesylate 1 mg/mL injection by Amneal Pharmaceuticals.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.